In the House, a proposal sponsored by Representatives Gus Bilirakis, Republican of Florida, and Kurt Schrader, Democrat of Oregon, would require the F.D.A. to work more closely with companies that want to make generic alternatives to drugs for which there is little competition. It would also give those manufacturers a six-month window during which no other generic drugmaker could compete. This month, , the health subcommittee of the House Energy and Commerce Committee voted to include that measure in its version of the user-fee bill.
While both proposals address some of the practices that have grabbed headlines, critics have noted that they would leave the brand-name pharmaceutical industry unscathed.
“This will have a minor impact,” said Ronny Gal, a Wall Street analyst for Bernstein who covers the drug industry.
Requiring notice when drug prices go up.
A bipartisan bill introduced by Senator John McCain, Republican of Arizona, and others would require that drug companies give notice and provide justification whenever their prices rise by a certain amount. The brand-name pharmaceutical industry opposes it.
Importing drugs from outside the United States.
The United States pays more for prescription drugs than virtually anywhere else. So some members of Congress, including Senator Bernie Sanders of Vermont, have proposed allowing Americans to import those cheaper drugs.
The pharmaceutical industry said the measures could lead to the importing of unsafe drugs. The four most recent commissioners of the F.D.A. have also opposed them.
The Senate health committee rejected Mr. Sanders’s proposal to include the measure in its user-fee bill this month, and without significant Republican support, the idea is not likely to gain traction.
Requiring pharmacy benefit managers to be more transparent.